TeraRecon to Sell EnvoyAI Platform
|
By HospiMedica International staff writers Posted on 12 Dec 2017 |

Image: TeraRecon has entered into a distribution partnership with EnvoyAI to sell and market the EnvoyAI platform (Photo courtesy of TeraRecon).
TeraRecon (Foster City, CA, USA), a provider of advanced visualization solutions, has entered into a distribution partnership with EnvoyAI (Cambridge, MA, USA) to sell and market the EnvoyAI platform. The platform includes a content-rich artificial intelligence (AI) marketplace, called the EnvoyAI Exchange, as well as a suite of market-ready AI-enablement technologies aimed at fostering broader access and clinical use of medical imaging algorithms within busy radiology practices.
TeraRecon provides advanced visualization, image viewing and post-processing solutions that leverage AI to improving radiology workflow through personalized automation features for increased efficiency. EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end-users. It facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.
As a distributor of EnvoyAI, TeraRecon will offer instant access to the platform containing more than 35 algorithms and initially focus on driving sales on two FDA-cleared algorithms from Imbio and icometrix, as well as one of its own cleared algorithms. Imbio offers lung density reporting for COPD analysis with chest CT scans. The Imbio CT Lung Density Analysis software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support for diagnosis and follow up examinations. icometrix offers icobrain, an FDA-cleared brain MRI tool that is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. The software is intended to automate the current manual process of identifying, labeling and quantifying the volumes of segmentable brain structures identified on MR images. TeraRecon offers iNtuition Time Density Analysis for CT, which supports stroke triage workflow by producing colorized parametric maps of the brain from time-resolved, thin-slice CT scans of the head with contrast, including CBF, CBV, MTT, TTP, TOT, RT map types.
“The automated outputs from Imbio and icometrix elevate the standard of care without creating additional work for radiologists,” said Jeff Sorenson, President and CEO of TeraRecon. “The combined workflows achieved by TeraRecon and EnvoyAI deliver these results in a fast, flexible, and extensible way allowing our customers to easily introduce AI into their medical imaging enterprise.”
TeraRecon provides advanced visualization, image viewing and post-processing solutions that leverage AI to improving radiology workflow through personalized automation features for increased efficiency. EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end-users. It facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.
As a distributor of EnvoyAI, TeraRecon will offer instant access to the platform containing more than 35 algorithms and initially focus on driving sales on two FDA-cleared algorithms from Imbio and icometrix, as well as one of its own cleared algorithms. Imbio offers lung density reporting for COPD analysis with chest CT scans. The Imbio CT Lung Density Analysis software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support for diagnosis and follow up examinations. icometrix offers icobrain, an FDA-cleared brain MRI tool that is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. The software is intended to automate the current manual process of identifying, labeling and quantifying the volumes of segmentable brain structures identified on MR images. TeraRecon offers iNtuition Time Density Analysis for CT, which supports stroke triage workflow by producing colorized parametric maps of the brain from time-resolved, thin-slice CT scans of the head with contrast, including CBF, CBV, MTT, TTP, TOT, RT map types.
“The automated outputs from Imbio and icometrix elevate the standard of care without creating additional work for radiologists,” said Jeff Sorenson, President and CEO of TeraRecon. “The combined workflows achieved by TeraRecon and EnvoyAI deliver these results in a fast, flexible, and extensible way allowing our customers to easily introduce AI into their medical imaging enterprise.”
Latest AI News
- FDA-Cleared AI System Detects Sepsis Earlier and Reduces Mortality
- Facial Image Analysis Tracks Biological Aging, Predicts Cancer Outcomes
- AI Model Uses Eye Imaging to Identify Risk of Major Systemic Diseases
- AI Platform Interprets Real-Time Wearable Data for Parkinson’s Management
- Algorithm Identifies Cardiac Arrest Hotspots to Guide AED Placement
- AI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
- Machine Learning Approach Enhances Liver Cancer Risk Stratification
- New AI Approach Monitors Brain Health Using Passive Wearable Data
- AI Tool Maps Early Risk Patterns in Bloodstream Infections
- AI Model Identifies Rare Endocrine Disorder from Hand Images
Channels
Artificial Intelligence
view channel
FDA-Cleared AI System Detects Sepsis Earlier and Reduces Mortality
Sepsis remains one of the deadliest complications for hospitalized patients, in part because its early signs overlap with other conditions. Each hour of delayed recognition measurably decreases survival,... Read moreFacial Image Analysis Tracks Biological Aging, Predicts Cancer Outcomes
Biological aging is the progressive loss of physiological function that may diverge from chronological age. In cancer care, clinicians need simple tools that reflect dynamic changes in patient resilience... Read moreCritical Care
view channel
AI Tool Predicts Risk of Out-of-Hospital Cardiac Arrest
Sudden cardiac arrest is a lethal event that often occurs without warning, causing more than 400,000 deaths in the U.S. each year and a survival rate of about 10%. Clinicians struggle to identify who in... Read more
Wearable Defibrillator Supports Quicker Beta-Blocker Optimization in Women
Women with newly diagnosed heart failure with reduced ejection fraction (HFrEF) often do not reach optimal beta-blocker dosing during early treatment. Guideline-directed titration depends on achieving... Read moreSurgical Techniques
view channel
Handheld AI Endomicroscope Enables Real-Time Precancer Detection at Point of Care
Many epithelial cancers are detected late because current diagnostics rely on invasive biopsies and in vivo microscopy with narrow field and shallow depth of field. These constraints can make it difficult... Read more
Intravascular Lithotripsy Catheter Advances Treatment of Calcified Coronary Disease
Calcified coronary artery disease complicates revascularization by impeding device deliverability and lesion crossing, particularly in tortuous vessels. Coronary artery disease is the leading cause of... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EHR-Integrated Screening Workflow Detects Cognitive Impairment at Admission
Cognitive impairment involves difficulties with thinking, learning, memory, and decision-making, and is more common in older adults. In U.S. hospitals, more than 40% of admitted older adults have dementia,... Read more
AI System Detects and Quantifies Chronic Subdural Hematoma
Viz.ai (San Francisco, CA, USA) announced a strategic commercialization collaboration with Johnson & Johnson (New Brunswick, NJ, USA) to expand access in the United States to the Viz Subdural solution... Read more
Continuous Monitoring Platform Detects Infection Risk Across Care Transitions
Patients leaving skilled nursing facilities often lose continuous physiologic monitoring, increasing the risk of undetected infection and delayed intervention. Nursing home residents are seven times more... Read more
Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings
Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read morePoint of Care
view channel
Point-of-Care Viscoelastic Testing System Supports Obstetric Bleeding Management
HemoSonics (Durham, NC, USA) announced on May 5, 2026 that the company's Quantra Hemostasis System for Obstetric Procedures won Silver in the 2026 Edison Awards in the Women’s Health and Reproductive Innovations... Read moreBusiness
view channel
Olympus Partnership Aims to Expand Access to Robot-Assisted Endoscopic Therapy
Olympus has signed an exclusive global distribution agreement with EndoRobotics Co., Ltd., under which robot-assisted technologies developed by EndoRobotics will be distributed worldwide as part of the... Read more







